Generated by AI
Pharming Group N.V. ADR is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. Its current portfolio centers on protein replacement therapies and precision medicines, with products designed to address conditions that have limited treatment options. The company’s marketed medicines include RUCONEST, used for acute hereditary angioedema, and Joenja, an oral therapy for APDS, reflecting its emphasis on specialist treatments for underserved patient groups. Pharming Group also operates across clinical development, manufacturing, regulatory affairs, and commercialization, supporting the full lifecycle of its medicines. Based in Leiden, the Netherlands, Pharming Group N.V. ADR plays a role in the rare disease market by combining scientific development with commercial execution in the global healthcare sector.
WebsiteDarwinweg 24
Leiden, 2333 CR
Netherlands
The latest articles about PHAR.
Approval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kgJoenja is expected to become available to patients covered by the expanded indication in February 2027Marks another step in Pharming’s strategy to expand Joenja across age groups and international markets Leiden, the Netherlands, November 6, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announce
A rare-disease player with a stabilized core product is now targeting a market 26 times larger, fueled by cash generation that needs no external financing.
Summary of Oct 27's posts. Generated by AI.
No summary yet.
Summary of Jul 19's posts. Generated by AI.
No summary yet.
No summary yet.
Investors talking about PHAR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.